Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinurilimab in advanced solid tumors
NCT03596372Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of BAY 1834942 in solid tumor (advanced stage), gastric cancer (GC), colorectal cancer (CRC) and 1 more (5 arms), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent adverse events up to 40 months, Severity of treatment-emergent adverse events up to 40 months and 2 more. Started Jun 2018; status: completed.
02
Drugs
BAY 1834942
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03596372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596372.